NO20022799L - Antisens oligonukleotider - Google Patents

Antisens oligonukleotider

Info

Publication number
NO20022799L
NO20022799L NO20022799A NO20022799A NO20022799L NO 20022799 L NO20022799 L NO 20022799L NO 20022799 A NO20022799 A NO 20022799A NO 20022799 A NO20022799 A NO 20022799A NO 20022799 L NO20022799 L NO 20022799L
Authority
NO
Norway
Prior art keywords
oligonucleotides
antigen
antigen oligonucleotides
inhibiting
expression
Prior art date
Application number
NO20022799A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022799D0 (no
Inventor
Rajinder Beri
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20022799D0 publication Critical patent/NO20022799D0/no
Publication of NO20022799L publication Critical patent/NO20022799L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20022799A 1999-12-15 2002-06-12 Antisens oligonukleotider NO20022799L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9929487.8A GB9929487D0 (en) 1999-12-15 1999-12-15 Antisense oligonucleotides
PCT/GB2000/004741 WO2001044455A2 (en) 1999-12-15 2000-12-12 Antisense oligonucleotides for the inhibition of expression of type i procollagen

Publications (2)

Publication Number Publication Date
NO20022799D0 NO20022799D0 (no) 2002-06-12
NO20022799L true NO20022799L (no) 2002-06-12

Family

ID=10866254

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022799A NO20022799L (no) 1999-12-15 2002-06-12 Antisens oligonukleotider

Country Status (17)

Country Link
US (1) US7173122B2 (de)
EP (3) EP1244781B1 (de)
JP (1) JP2003516752A (de)
KR (1) KR20020064936A (de)
CN (1) CN1423695A (de)
AT (2) ATE410510T1 (de)
AU (1) AU2529701A (de)
BR (1) BR0016347A (de)
CA (1) CA2390674A1 (de)
DE (2) DE60023943T2 (de)
GB (1) GB9929487D0 (de)
IL (1) IL149640A0 (de)
MX (1) MXPA02005871A (de)
NO (1) NO20022799L (de)
NZ (1) NZ519008A (de)
WO (1) WO2001044455A2 (de)
ZA (1) ZA200203878B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396823B2 (en) * 1999-12-15 2008-07-08 Nath Rahul K Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis
CN111378657B (zh) * 2018-12-28 2024-03-15 苏州瑞博生物技术股份有限公司 抑制COL1A1基因表达的siRNA、含有该siRNA的药物组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011149A1 (en) 1991-12-03 1993-06-10 Thomas Jefferson University Methods of detecting a genetic predisposition for osteoporosis
US6265157B1 (en) * 1991-12-03 2001-07-24 Allegheny University Of The Health Sciences Compositions and methods for detecting altered COL1A1 gene sequences
EP0674705A4 (de) * 1992-11-09 1997-11-26 Univ Jefferson Antisense-oligonukleotide zur hemmung der expression mutierter gene und wildtypgene des collagens.
WO1994022487A1 (en) * 1993-03-26 1994-10-13 Thomas Jefferson University Use of a col 1a1 mini-gene construct to inhibit collagen synthesis
ATE206131T1 (de) * 1995-03-13 2001-10-15 Aventis Pharma Gmbh Phosphonomonoesternnukleinsäuren, verfahren zu ihrer herstellung und ihre verwendung
DE19508923A1 (de) * 1995-03-13 1996-09-19 Hoechst Ag Phosphonomonoesternukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0736608A1 (de) * 1995-04-08 1996-10-09 Roche Diagnostics GmbH Verfahren zur spezifischen Vervielfältigung und zum Nachweis von DNA bzw. RNA
EP0856579A1 (de) 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden
US6238921B1 (en) 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
US6007995A (en) * 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
CN1285612C (zh) * 1999-11-12 2006-11-22 法布罗根股份有限公司 动物胶原和明胶

Also Published As

Publication number Publication date
GB9929487D0 (en) 2000-02-09
NO20022799D0 (no) 2002-06-12
MXPA02005871A (es) 2002-10-23
EP2025752A2 (de) 2009-02-18
ATE309338T1 (de) 2005-11-15
JP2003516752A (ja) 2003-05-20
EP1244781B1 (de) 2005-11-09
DE60023943T2 (de) 2006-08-03
CN1423695A (zh) 2003-06-11
BR0016347A (pt) 2002-09-10
NZ519008A (en) 2004-04-30
CA2390674A1 (en) 2001-06-21
ATE410510T1 (de) 2008-10-15
DE60040495D1 (de) 2008-11-20
EP1244781A2 (de) 2002-10-02
EP1698695B1 (de) 2008-10-08
WO2001044455A3 (en) 2002-01-10
ZA200203878B (en) 2003-08-15
US7173122B2 (en) 2007-02-06
WO2001044455A2 (en) 2001-06-21
AU2529701A (en) 2001-06-25
EP1698695A3 (de) 2007-02-14
US20030105050A1 (en) 2003-06-05
DE60023943D1 (de) 2005-12-15
KR20020064936A (ko) 2002-08-10
EP1698695A2 (de) 2006-09-06
IL149640A0 (en) 2002-11-10
EP2025752A3 (de) 2009-08-12

Similar Documents

Publication Publication Date Title
ATE442152T1 (de) Antisense-entwurf
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
DK0731835T3 (da) Antisense-oligonukleotider med tumorigenicitetshæmmende virkning
ATE508188T1 (de) Oligonukleotid-zusammensetzungen mit verbesserter wirksamkeit
NO965080D0 (no) Antisens oligonukleotidmodulering av genekspresjon
EP1750771A4 (de) Pankreasinsel-mikro-rna und verfahren zu ihrer unterdrückung
EP1569695A4 (de) Antisense-modulationder apolipoprotein-b-expression
ATE428780T1 (de) Verfahren zur zubereitung von antisense oligonukleotiden
DE69628864D1 (de) Invertierte chimäre und hybrid-oligonukleotide
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
ATE216705T1 (de) Antisense-oligonukleotidmodulation der raf- genexpression
NO983716L (no) Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
DK1011723T3 (da) 88KDA tumorgen vækstfaktor og antagonister
WO2000017233A3 (de) Gene des 1-desoxy-d-xylulose-biosynthesewegs
EP1142591A4 (de) Genträger
TR199802648A3 (tr) Gen tedavisi için nüklein asit yapilari.
PT775745E (pt) Aptameros inibidores de catepsina g
NO20022799L (no) Antisens oligonukleotider
EP1076093A4 (de) Gen der sakaranetin-synthase
GB0218803D0 (en) Targeted gene modification by single-standed DNA oligonucleotides
EP1448762A4 (de) Antisense-modulation der expression des toll-ähnlichen rezeptors 4 erfindungsgebiet
IT1313568B1 (it) Microrganismi fago-resistenti e determinanti genetiche di fago-resistenza.
AU2001267387A1 (en) Nucleotide sequences which code for the coryneform acyl carrier protein gene
IT251114Y1 (it) Cinghia per prodotti di pelleteria .

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application